Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 6
2004 2
2005 3
2006 2
2007 2
2008 3
2010 1
2011 2
2012 1
2014 1
2015 1
2016 1
2017 1
2018 2
2019 2
2020 2
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Murakami K, Sasaki Y, Asahiyama M, Yano W, Takizawa T, Kamiya W, Matsumura Y, Anai M, Osawa T, Fruchart JC, Fruchart-Najib J, Aburatani H, Sakai J, Kodama T, Tanaka T. Murakami K, et al. Among authors: anai m. Cells. 2022 Feb 18;11(4):720. doi: 10.3390/cells11040720. Cells. 2022. PMID: 35203369 Free PMC article.
Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study.
Takao T, Yanagisawa H, Suka M, Yoshida Y, Onishi Y, Tahara T, Kikuchi T, Kushiyama A, Anai M, Takahashi K, Wakabayashi Sugawa S, Yamazaki H, Kawazu S, Iwamoto Y, Noda M, Kasuga M. Takao T, et al. Among authors: anai m. J Diabetes Investig. 2022 Feb;13(2):299-307. doi: 10.1111/jdi.13659. Epub 2021 Oct 7. J Diabetes Investig. 2022. PMID: 34533892 Free PMC article.
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
Kitazawa T, Seino H, Ohashi H, Inazawa T, Inoue M, Ai M, Fujishiro M, Kuroda H, Yamada M, Anai M, Ishihara H. Kitazawa T, et al. Among authors: anai m. Diabetes Obes Metab. 2020 Sep;22(9):1659-1663. doi: 10.1111/dom.14059. Epub 2020 May 7. Diabetes Obes Metab. 2020. PMID: 32314464 Free PMC article. Clinical Trial.
Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2.
Osawa T, Shimamura T, Saito K, Hasegawa Y, Ishii N, Nishida M, Ando R, Kondo A, Anwar M, Tsuchida R, Hino S, Sakamoto A, Igarashi K, Saitoh K, Kato K, Endo K, Yamano S, Kanki Y, Matsumura Y, Minami T, Tanaka T, Anai M, Wada Y, Wanibuchi H, Hayashi M, Hamada A, Yoshida M, Yachida S, Nakao M, Sakai J, Aburatani H, Shibuya M, Hanada K, Miyano S, Soga T, Kodama T. Osawa T, et al. Among authors: anai m. Cell Rep. 2019 Oct 1;29(1):89-103.e7. doi: 10.1016/j.celrep.2019.08.087. Cell Rep. 2019. PMID: 31577958 Free article.
Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.
Ishihara H, Anai M, Seino H, Kitazawa T, Ohashi H, Ai M, Inoue M, Fujishiro M, Inazawa T, Kuroda H, Yamada M. Ishihara H, et al. Among authors: anai m. Diabetes Ther. 2018 Oct;9(5):2117-2125. doi: 10.1007/s13300-018-0491-4. Epub 2018 Aug 25. Diabetes Ther. 2018. PMID: 30145651 Free PMC article.
40 results